Journal of Pharmaceutical Health Care and Sciences最新文献

{"title":"A comparative study of the effectiveness of virtual reality-based and text-based training in sterile preparation: pilot trial of early-stage clinical VR study.","authors":"Satoru Esumi, Sari Nakagawa, Mai Ikemura, Yui Takezawa, Rika Ebara, Miho Harada, Akitoshi Tatsumi, Akiko Kanmachi, Yasuhiko Hashimoto, Mariko Takeda-Morishita","doi":"10.1186/s40780-026-00571-5","DOIUrl":"10.1186/s40780-026-00571-5","url":null,"abstract":"<p><p>BACKGROUND: This study is a pilot study evaluating the effectiveness of virtual reality (VR) applications in retraining sterile preparation techniques for injectable medications. Specifically, it focused on comparing VR-based learning with conventional text-based learning and objectively assessing students’ acquisition of practical skills using standardized evaluation criteria. METHODS: Seventeen pharmacy students voluntarily participated in the study and were divided into two groups: one using a VR application for learning and the other using text-based materials. Immediately after training with their respective tools, students’ aseptic preparation skills were assessed using standardized criteria (including 29 individual evaluation checkpoints) and a 5-point overall rating scale. RESULTS: Students who used the VR application completed tasks in a shorter time and scored higher on evaluation criteria such as operational smoothness and drug dissolution within vials. Additionally, multiple assessment items, including “Fill the aseptic smoothly and evenly, without stopping in the middle of the process,” were strongly correlated with the overall practical performance ratings of the VR group. CONCLUSIONS: The introduction of VR applications for aseptic preparation training, which involves complex procedures, suggests that VR-based learning may be more effective than traditional text-based methods in helping students understand procedural workflows and improve operational fluency. These findings indicate that VR technology may serve as a useful educational tool in practical pharmacy training. Further studies with larger sample sizes are needed to confirm these findings. TRIAL REGISTRATION: Not applicable </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13196225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with peripheral neuropathy development during gemcitabine plus albumin-bound paclitaxel therapy as first-line treatment for unresectable pancreatic cancer: a retrospective evaluation.","authors":"Tomoya Ban, Makoto Miura","doi":"10.1186/s40780-026-00572-4","DOIUrl":"10.1186/s40780-026-00572-4","url":null,"abstract":"<p><p>BACKGROUND: Gemcitabine plus albumin-bound paclitaxel is widely used as first-line therapy for unresectable pancreatic cancer, but it is frequently complicated by chemotherapy-induced peripheral neuropathy, which may lead to functional impairment and treatment modification. Factors associated with clinically relevant neuropathy, defined as grade 2 or higher, remain insufficiently clarified. This study aimed to identify factors associated with the development of grade ≥ 2 neuropathy during therapy. METHODS: We conducted a retrospective observational study using medical records of patients with unresectable pancreatic cancer who received this combination therapy at Rakuwakai Otowa Hospital from April 2015 to March 2024. Patient characteristics, treatment details, and neuropathy outcomes were collected. Univariate and multivariate logistic regression analyses were performed to evaluate factors associated with grade ≥ 2 neuropathy. Statistical significance was defined as P < 0.05. RESULTS: Fifty-seven patients were included in the analysis, and 19 patients (33.3%) developed grade ≥ 2 neuropathy. In multivariate logistic regression, a history of diabetes mellitus was significantly associated with the development of grade ≥ 2 neuropathy (odds ratio 3.89, 95% confidence interval 1.06–14.3, P = 0.041). No other clinical or treatment-related variables demonstrated significant associations. CONCLUSIONS: A history of diabetes mellitus may be associated with the development of grade ≥ 2 CIPN in patients with unresectable pancreatic cancer undergoing GnP therapy. Healthcare professionals should detect CIPN symptoms early and manage them appropriately, particularly in patients with diabetes mellitus. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13188612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study.","authors":"Yosuke Ando, Hiroki Banno, Satoe Yamaguchi, Akiko Ban, Kenji Katsuragawa, Ryo Sakurai, Yumiko Sato, Satoshi Nakamura, Toshinori Sasaki, Hirotaka Inoue, Satomi Kumazawa, Takuya Koyama, Saeko Harada, Etsuko Mishima, Hiroshi Matsuoka, Shigeki Yamada, Masayuki Miyazaki","doi":"10.1186/s40780-026-00569-z","DOIUrl":"10.1186/s40780-026-00569-z","url":null,"abstract":"<p><p>BACKGROUND: Zolbetuximab for CLDN18.2-positive advanced gastric cancer frequently causes chemotherapy-induced nausea and vomiting (CINV), particularly during the first infusion. Single-center studies in Japan have reported standardized infusion protocols and antiemetic strategies; however, these uniform approaches do not allow evaluation of how differences in infusion rate settings, antiemetic combinations, or patient backgrounds influence CINV. Using real-world data from multiple institutions with various clinical practices, the aim of this study was to clarify factors associated with CINV during the first zolbetuximab infusion, focusing on infusion rate, antiemetic use, and patient characteristics. METHODS: This multicenter retrospective study included patients with CLDN18.2-positive unresectable or recurrent gastric cancer who received zolbetuximab between June 2024 and April 2025. Clinical characteristics, gastrectomy status, infusion parameters, antiemetic use, and CINV events during the first infusion were extracted from electronic medical records. CINV severity was assessed using CTCAE or patient-reported scales (NRS and Faces Scale), depending on institutional practice. Accordingly, CTCAE Grade ≥ 2, NRS ≥ 3, or Faces Scale ≥ 6 were defined as moderate-or-greater nausea. Patient backgrounds were summarized using descriptive statistics. Associations between CINV and age group, sex, gastrectomy status, antiemetic combinations, and infusion-rate categories were evaluated with exploratory analyses using Fisher’s exact or χ2 tests. RESULTS: Forty-four patients were analyzed. CINV during the first zolbetuximab infusion was more frequent in patients without gastrectomy (38.7%) than in those with gastrectomy (7.7%). Younger age was associated with increased risk, whereas sex differences were minimal. Olanzapine use reduced the incidence of moderate-or-greater nausea or any-grade vomiting (18.2% vs 32.4%). CINV typically occurred when infusion rates reached approximately 200–250 mg/h, suggesting an increased risk when rates exceeded approximately 150 mg/h. Combined risk analysis showed that gastrectomy status had a stronger influence on CINV than age or sex, and olanzapine further reduced risk among non-gastrectomized patients. CONCLUSION: Infusion-phase CINV during the first zolbetuximab infusion was associated with both patient-related and administration-related factors in real-world practice. Quantitative evaluation of infusion-rate ranges and the influence of gastric mucosal status suggest that nausea severity may be partially modifiable through optimized infusion management and risk-adapted antiemetic strategies. These exploratory findings warrant prospective validation. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13188557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of utilizing electronic health databases in evidence-based practice among Iranian pharmacists: a survey by simulation of health-seeking pregnant women.","authors":"Hooman Pourbala, Ghader Mohammadnezhad, Hadi Esmaily","doi":"10.1186/s40780-026-00561-7","DOIUrl":"10.1186/s40780-026-00561-7","url":null,"abstract":"<p><p>BACKGROUND: Evidence-based medicine (EBM) applies the most reliable evidence available to support clinical decision-making, improving treatment outcomes, rational medication use, and reducing healthcare costs. OBJECTIVES: This study evaluated the knowledge, attitude, and practice (KAP) of Iranian community pharmacists regarding EBM utilization. METHODS: A 36-item questionnaire was designed and validated to assess the pharmacists’ knowledge and attitudes toward EBM. Practice was evaluated using a simulated-patient method one week after questionnaire completion. Multivariable linear regression was used to examine associations between pharmacist characteristics and knowledge and practice scores, with sensitivity analyses adjusting for geographic region. RESULTS: Within 284 pharmacy visits, data were obtained from 200 pharmacists aged 24–65 years. The average knowledge score was 37.91 ± 15.4 (out of 100). Pharmacists aged 24–29 demonstrated higher knowledge levels than those aged 30–65 (P = 0.042). Dispensing more than 30 prescriptions daily was associated with higher knowledge scores (P = 0.024). Pharmacists who reported using UpToDate® demonstrated higher knowledge and practice scores compared with non-users (P < 0.001). Attitudes toward EBM were overwhelmingly positive, indicating strong theoretical support despite reported implementation barriers. The mean practice score in managing the simulated-patient was 50.34 ± 21.35. A direct association was detected between knowledge and practice (r = 0.73, P < 0.05), whereas no association was observed between attitudes and practice. Multivariable analysis showed that younger age, higher prescription volume, and use of UpToDate® were independently associated with higher knowledge and practice scores. CONCLUSION: Most pharmacists support EBM; however gaps in knowledge and practice remain. Use of structured electronic resources such as UpToDate® were associated with improved knowledge and practice. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13047831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in prescription patterns and drug costs following the launch of generic pemetrexed products: a retrospective study in Japan.","authors":"Toshikazu Ichie, Daisuke Suzuki, Shuji Yamashita, Kunio Naruse, Hideki Hayashi","doi":"10.1186/s40780-026-00570-6","DOIUrl":"10.1186/s40780-026-00570-6","url":null,"abstract":"<p><p>BACKGROUND: Pemetrexed (PEM) is an antimetabolite antineoplastic agent that has been available in generic form in Japan since June 2021. As a hazardous drug (HD), the use of a closed-system transfer device (CSTD) is recommended. Some generics, including 800-mg vials, are not available for the original product; however, changes in prescribing patterns following the introduction of generics remain unclear. This study examined the prescription volume and drug costs of PEM before and after the launch of generics. METHODS: Clinical data were analyzed using the MDV analyzer® (Medical Data Vision Co., Ltd.). Patients who received PEM between June 2020 and May 2023 were enrolled. Study outcomes included the number of prescriptions, dose per prescription, drug costs (yen), and vials used. Data were categorized into original PEM, generics without 800-mg vials, and generics with 800-mg vials. RESULTS: A total of 89,078 prescriptions were analyzed. In the last 3 months of the study, prescription counts (proportions) were 966 (14.8%) for original PEM, 404 (6.2%) for generics without 800-mg vials, and 5,155 (79.0%) for generics with 800-mg vials. The mean prescribed doses were 773.2 mg, 789.6 mg, and 777.8 mg, respectively. The mean drug costs were 193,683 yen, 84,583 yen, and 78,770 yen, respectively. The average numbers of vials per prescription, calculated from the total number of vials and prescriptions, were 3.4, 3.5, and 2.3, respectively, indicating that generics with 800-mg vials were associated with approximately one fewer vial per prescription compared to other groups. CONCLUSIONS: After the introduction of generics, a shift in prescription patterns was observed, with an increasing proportion of products with 800-mg vials. Although mean prescribed doses were similar across groups, generics with 800-mg vials appeared to be more cost-effective and utilized fewer vials per prescription within this study population. The reduction in the number of vials suggests a potential decrease in CSTD use, which could contribute to lowering material costs. These results provide important insight for future drug development and for strategies aimed at reducing healthcare expenditures, including material costs. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of the mini-mental state examination for assessing cognitive function in determining appropriate medication management strategies in patients with heart failure: a retrospective observational study.","authors":"Naoya Ashikawa, Kana Inagaki, Yusuke Oka, Takashi Doi, Takayo Kawane, Yuko Sago","doi":"10.1186/s40780-026-00567-1","DOIUrl":"10.1186/s40780-026-00567-1","url":null,"abstract":"<p><p>BACKGROUND: Patients with heart failure frequently experience recurrent hospitalizations, with poor medication adherence serving as a primary determinant of adverse clinical outcomes. Given the elevated prevalence of cognitive impairment among elderly patients with heart failure, the implementation of individualized medication management strategies is imperative. This study aimed to elucidate the association between Mini-Mental State Examination (MMSE) scores and the feasibility of various medication management strategies in hospitalized patients with heart failure. METHODS: This retrospective observational study analyzed 148 patients with heart failure aged ≥ 65 years. Subjects were categorized into three groups based on their medication management at discharge: self-management via medication envelopes (press-through-package sheets or unit-dose packaging), self-management using a medication calendar, or nurse-assisted administration. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were performed to identify predictors of self-management feasibility. RESULTS: The MMSE score was the sole parameter showing significant differences across all pairwise comparisons between management groups. Multivariate analysis identified the MMSE score as an independent predictor for both self-management via envelopes and the necessity of adherence aids. For self-management utilizing medication envelopes, ROC analysis yielded an area under the curve (AUC) of 0.848, with an optimal cutoff threshold of ≥ 27 (sensitivity: 78.6%; specificity: 80.2%). For the broader feasibility of self-administration (using either envelopes or calendar), the AUC was 0.820, with a threshold of ≥ 24 (sensitivity: 83.7%; specificity: 67.9%). Additionally, patients of heart failure-related readmission associated with poor adherence occurred exclusively when established management protocols were discontinued post-discharge. CONCLUSIONS: MMSE scores may represent a valuable tool for predicting the successful establishment of medication management strategies. Specifically, scores below 27 suggest a need for adherence aids like medication calendar, while scores below 24 indicate a substantial requirement for external caregiver or nursing assistance to ensure therapeutic adherence. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database.","authors":"Nao Takatsu, Jun Matsumoto, Yurie Oka, Tomonori Sakai, Naohiro Iwata, Tsukasa Higashionna, Tatsuaki Takeda, Hirofumi Hamano, Yoshito Zamami","doi":"10.1186/s40780-026-00565-3","DOIUrl":"10.1186/s40780-026-00565-3","url":null,"abstract":"<p><p>BACKGROUND: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas with poor prognosis, particularly in patients with relapsed or refractory (R/R) disease. Romidepsin and tucidinostat are histone deacetylase inhibitors used to treat R/R PTCL. No head-to-head post-marketing surveillance studies have compared adverse events (AEs) between the two agents. In this brief report, the AE profiles of romidepsin and tucidinostat were compared using the Japanese Adverse Drug Event Report (JADER) database to facilitate their differentiation and promote the management of AEs. METHODS: We conducted a descriptive analysis using data from the JADER database from April 2018 to July 2025. The reported AEs for romidepsin and tucidinostat were extracted and classified according to preferred terms (PTs) and system organ classes (SOCs). Reporting odds ratios with 95% confidence intervals were calculated to compare the AE profiles between the groups. RESULTS: In total, 998,397 reports were analysed for all drugs, including 323 for romidepsin and 753 for tucidinostat. Compared with all drugs, both agents showed significant disproportionality signals in four SOCs: Blood and lymphatic system disorders; General disorders and administration site conditions; Investigations; and Neoplasms benign, malignant and unspecified. Romidepsin exhibited additional significant signals in six SOCs: Cardiac disorders, Eye disorders, Gastrointestinal disorders, Immune system disorders, Infections and infestations, and Metabolism and nutrition disorders. Direct comparison between the two agents revealed broader AE profiles for romidepsin, with AEs more frequently reported in eight SOCs, whereas tucidinostat showed AEs in only two SOCs. Romidepsin was associated with AEs more frequently reported in several PTs, including atrial fibrillation and gastrointestinal toxicities, such as constipation, tumour lysis syndrome, hepatotoxicity, and peripheral neuropathy, which was consistent with the results at the SOC level. In contrast, several significant PTs for tucidinostat were observed in General disorders and administration site conditions and Investigations. CONCLUSIONS: The Japanese real-world pharmacovigilance analysis showed differences in the AE profiles between romidepsin and tucidinostat. These differences in safety profiles may be useful for treatment selection and AE management in routine clinical practice among patients with R/R PTCL. Further studies are warranted to confirm these findings and better characterise the safety profiles of these agents. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147530142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokine release syndrome-compatible fever after initiation of local radiotherapy during late-phase epcoritamab therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report.","authors":"Naoaki Nishimura, Hajime Nakashima, Yuto Ogasa, Kenji Yoshikuni, Kentaro Kohno, Ryosuke Ogawa","doi":"10.1186/s40780-026-00568-0","DOIUrl":"10.1186/s40780-026-00568-0","url":null,"abstract":"<p><p>BACKGROUND: Epcoritamab, a subcutaneous CD3×CD20 bispecific antibody, has demonstrated promising activity in relapsed or refractory diffuse large B‑cell lymphoma. Cytokine release syndrome (CRS) is a key adverse event associated with T‑cell–engaging therapies; however, it typically occurs early after treatment initiation and is generally manageable with step‑up dosing and premedication. Evidence regarding the safety of delivering radiotherapy during late-phase epcoritamab therapy remains limited. CASE PRESENTATION: A 58-year-old man with diffuse large B-cell lymphoma received epcoritamab. On cycle 8 day 8, local radiotherapy (40 Gy in 20 fractions) was initiated for a residual abdominal lymph node lesion. Approximately 12 h after the second radiotherapy fraction, he developed fever (38 °C) and fatigue without hypotension or hypoxia and without neutropenia, consistent with a CRS-compatible febrile episode (grade 1 by the American Society for Transplantation and Cellular Therapy criteria). Blood cultures were obtained and empiric cefepime with acetaminophen was initiated, resulting in transient defervescence; however, fever recurred approximately 12 h after the third radiotherapy fraction. Blood cultures, (1,3)-β-D-glucan, and galactomannan assays were negative. Given the reproducible temporal association with radiotherapy, a CRS-compatible event was considered, and tocilizumab (8 mg/kg) was administered in line with standard CRS management guidance, with defervescence within 1 h. He remained afebrile thereafter and completed radiotherapy without recurrence. CONCLUSIONS: CRS-compatible fever is uncommon after multiple cycles of epcoritamab. This case suggests a temporal association between radiotherapy and a CRS-compatible febrile episode during late-phase therapy and supports the possibility that radiotherapy acted as an inflammatory trigger. When radiotherapy is delivered during bispecific antibody therapy, fever should prompt concurrent evaluation for infection while keeping CRS in the differential diagnosis, and standard CRS management should be applied promptly when clinically indicated. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13059281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147530078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehension of medication-related information translated from Japanese to Southeast Asian Languages using google translate.","authors":"Yumina Ako, Takafumi Sugawara, Sho Ishida, Kazuyuki Tanaka, Atsushi Watanabe","doi":"10.1186/s40780-026-00559-1","DOIUrl":"10.1186/s40780-026-00559-1","url":null,"abstract":"<p><strong>Background: </strong>A workforce of foreign workers, mainly from Southeast Asia (SEA), is increasing because of an aging society and a declining birthrate. However, there are a few hospitals that can accept them. In this study, we evaluated whether SEA persons can understand medication-related information translated from Japanese into SEA languages using Google Translate.</p><p><strong>Methods: </strong>The study was a questionnaire survey of simulated cases. Information on simulated cases in Japanese was translated into each target language using Google Translate. We set the answer to the questionnaire based on the simulated cases. Participants' backgrounds and answers to the questionnaire were aggregated for each target language and category.</p><p><strong>Results: </strong>The participants were 24 people from Thailand, Vietnam, Indonesia, and Burma. Comprehension outcomes differed across medications and information types. While understanding of main effects and side effects was generally adequate, comprehension of medication usage was limited, particularly for loxoprofen, with substantial variation across language groups.</p><p><strong>Conclusions: </strong>It's challenging to communicate medical information accurately to the SEA patients when relying solely on Google Translate. Therefore, we may need to provide medication guidance orally to improve and enhance medication-related information, even if we cannot speak SEA languages.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"12 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13003729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review.","authors":"Chiaki Imai, Masashi Uchida, Koji Takahashi, Izumi Ohno, Yuichi Takiguchi, Itsuko Ishii","doi":"10.1186/s40780-026-00564-4","DOIUrl":"10.1186/s40780-026-00564-4","url":null,"abstract":"<p><p>BACKGROUND: The overall incidence of pituitary apoplexy among patients with pituitary adenoma ranges from 0.6% to 7.0%, although many cases likely go undiagnosed. Several precipitating factors have been identified, and a small number of case reports have suggested an association between immune checkpoint inhibitors and pituitary apoplexy, particularly in patients with preexisting adenoma. Moreover, the safety of immune checkpoint inhibitor rechallenge remains uncertain. CASE PRESENTATION: The patient was a 71-year-old woman with a recurrence of metastatic primary rectal melanoma. A pituitary tumor had been identified before initiation of systemic therapy. Following the second cycle of nivolumab plus ipilimumab, the patient developed headache, nausea, and vomiting, followed by decreased serum thyroid-stimulating hormone, adrenocorticotrophic hormone, and luteinizing hormone levels. These findings were consistent with evolving hypopituitarism. Contrast-enhanced magnetic resonance images revealed hemorrhage in the pituitary adenoma, suggesting pituitary apoplexy. Eight months after discontinuation of nivolumab plus ipilimumab, disease progression was noted, and nivolumab monotherapy was resumed. There was no recurrence of pituitary apoplexy during six cycles of nivolumab. CONCLUSIONS: This case highlights that pituitary apoplexy can occur temporally after nivolumab plus ipilimumab treatment in patients with preexisting pituitary adenoma. Importantly, nivolumab monotherapy rechallenge under close monitoring may be feasible without recurrence of pituitary apoplexy. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}